The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1

Clinical Infectious Diseases

Volumn 56, Issue 2, 2013, Pages 228-235

  Kieran, Jennifer ^a   Schmitz, Susanne ^a   O'Leary, Aisling ^b   Walsh, Cathal ^a   Bergin, Colm ^b   Norris, Suzanne ^b   Barry, Michael ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

Bayesian; HCV protease inhibitors; hepatitis C; Ireland; meta analysis

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; ARTICLE; BAYES THEOREM; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RELAPSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS STRAIN;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; OLIGOPEPTIDES; PROLINE; RECURRENCE; TREATMENT OUTCOME;

EID: 84871817621     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis880     Document Type: Article

References (30)

1. World Health Organization. Hepatitis C. Fact Sheet No. 164. July 2012. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed 22 October 2012.
2. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48:148-62. (Pubitemid 350191999)
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67. (Pubitemid 41196755)
4. European Association for the Study of the Liver Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-64.
5. Ghany MND, Strader D, Thomas D, Seeff L. An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65. (Pubitemid 32913521)
9. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54:96-104.
10. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
11. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
12. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-16.
13. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
14. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with pe-ginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J Med 2009; 360:1827-38.
15. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362:1292-303.
16. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
17. Flamm SL, Lawitz E, Jacobson I, et al. High sustained viral response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alpha-2A/ribavirin. J Hepatol 2011; 54:S541-2.
18. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-50.
19. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56:78-84.
20. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001; 10:277-303. (Pubitemid 32691157)
21. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24:1-19. (Pubitemid 43197227)
22. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23:3105-24. (Pubitemid 39334902)
23. Schmitz S, Adams R, Walsh CD, Barry M, Fitzgerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis 2012; 71:225-30.
24. Systematic reviews. 2009 ed. University of York, UK: Centre for Reviews and Dissemination, 2009.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264-9, W64.
26. Cochrane handbook for systematic reviews of interventions version 5.1.0. In: Higgins JPT, Green S, eds. The Cochrane Collaboration, 2011.
27. Pol SAJ, Zeuzem S. Similar SVR rates in IL28B CC, CT or TT prior relapser, partial-or null-responder patients treated with telaprevir/pe- ginterferon: retrospective analysis of the REALIZE study. Program and abstracts of the 46th Annual Meeting of the European Association for the Study of the Liver, 30 March 2011.
28. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007; 26:1237-54. (Pubitemid 46380839)
29. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10:325-37.
30. Poordad FBJ, Gordon SC. IL28B genotype predicts lead-in response, likelihood of shortened therapy in SPRINT-2 and RESPOND-2 phase III boceprevir trials. Program and abstracts of the 46th Annual Meeting of the European Association for the Study of the Liver, 30 March 2011.